We’re restoring the true meaning of healthcare—developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases. See how we're connecting the best of Health&Care for every patient and provider. https://lnkd.in/eW-mXA49
About us
At Johnson & Johnson Innovative Medicine, we are leading where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK
- Website
-
https://www.janssen.com/johnson-johnson-innovative-medicine
External link for Johnson & Johnson Innovative Medicine
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001 employees
- Type
- Privately Held
Employees at Johnson & Johnson Innovative Medicine
Updates
-
Today marks the 34th anniversary of the Americans with Disabilities Act (ADA), dedicated to ensuring people with disabilities are given equal rights and opportunities as their abled peers. Individuals in the low-vision community and others impacted by the ADA deserve accessible options in all areas of life but often experience barriers when it comes to accessing information digitally. To help support inclusivity and #Accessibilty, we’re sharing digital best practices to implement today and every day: https://bit.ly/46iLbiZ #ADA34
-
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for a new treatment for adult patients with #PulmonaryArterialHypertension (PAH). This significant milestone furthers our decades-long commitment to the PH community and fulfills our pledge to provide treatments that address all three foundational pathways for this progressive disease. Learn more here: https://bit.ly/4fljBp7 #JNJCardiopulmonary
-
-
Some dermatologic conditions can present differently across skin tones – leading to misdiagnoses or delays in treatment. Increasing diversity in the physician workforce is one way to help improve patient experiences and health outcomes. We’re proud to continue our collaboration with American Academy of Dermatology on Pathways: Inclusivity in Dermatology, a program that helps students from Black, Latino, and Indigenous communities learn more about careers in dermatology. This summer, we had the pleasure of meeting with 65 students in Chicago and Washington, D.C., and were inspired by their passion, engagement and interest in creating a more diverse future in #dermatology. Learn more: https://bit.ly/3WAqxYb
-
Today we submitted a supplemental New Drug Application to the U.S. FDA for a monotherapy option for adults living with treatment-resistant depression (TRD). People living with TRD, a form of major depressive disorder, often spend far too long cycling through multiple treatments that don’t effectively resolve their symptoms. We are proud to continue advancing treatment innovation for those deeply impacted by this difficult and complex condition. Learn more: https://bit.ly/3Lv60hw #JNJNeuroscience #MentalHealth #MDD
-
At Johnson & Johnson, we’re passionate about supporting those living with #PulmonaryHypertension (PH). As a company, we pride ourselves in never losing sight of the people behind the disease and the potential for impacting their lives motivates every choice we make. Visit our PH Human site to learn more about our efforts: https://bit.ly/46eDytD #JNJCardiopulmonary
-
-
New research, conducted in collaboration with The Sheffield University and published by Pulmonary Vascular Research Institute (PVRI), describes the clinical characteristics, healthcare resource utilization and costs, health-related quality of life, and survival for patients with #PAH, reinforcing the importance of our commitment to the PH community. Learn more about the outcomes here: https://bit.ly/4cOj2T8 #JNJCardiopulmonary #PulmonaryCirculation #PCJournal
-
-
#News: Johnson & Johnson reported Second Quarter 2024 earnings results recently We achieved significant Innovative Medicine pipeline milestones and strengthened our portfolio of marketed medicines in meaningful ways with new approvals. Together with our partners, we remain committed to developing treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. Explore our results here: https://lnkd.in/eriyG_zy #JNJ #Earnings
-
Today, we completed the acquisition of Yellow Jersey Therapeutics, gaining ownership of NM26 and building our leadership in atopic dermatitis. Learn more: https://bit.ly/3XY8Tyz #JNJImmunology
-
-
Calling all entrepreneurs, innovators and academics! Join Johnson & Johnson for the first webinar in our Innovation Ignited series on July 24: Conversations in Precision Medicine - Digital Diagnostics for Neuroscience If you’ve ever wondered how J&J leverages strategic collaborations to lead the way in healthcare innovation, this webinar series is the perfect opportunity to find out. RSVP today: https://lnkd.in/gcFxNYXm
-